SCHEMBL8110482

SCHEMBL8110482

CCC(Oc1ccccc1)C(=O)Nc1ccc2[nH]c3c(c2c1)CC(CNC(C)C)CC3

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
HSD17B10 Q99714 2/20 0.41
POLB P06746 2/20 0.41
HTR1F P30939 1/20 0.41
MAPT P10636 3/20 0.40
TSHR P16473 1/20 0.40
ALDH1A1 P00352 5/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
VPS4B O75351 1/20 0.39
VCP P55072 1/20 0.39
NPC1 O15118 1/20 0.39
USP2 O75604 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8110483 0.82 MAPT (0.44) LMNAHTTMEN1KMT2AHTR1F
Hydrochloric Acid SCHEMBL8101396 0.81 VPS4B (0.42) LMNAMEN1KMT2AHTR1FMAPT
SCHEMBL8101244 0.80 LMNA (0.38) LMNAHTTMEN1KMT2AHSD17B10
SCHEMBL8101236 0.77 LMNA (0.37) LMNAHTTMEN1KMT2AHSD17B10
Bromide SCHEMBL8100818 0.76 RORC (0.43) LMNAHTR1FALDH1A1VPS4BVCP
Hydrochloric Acid SCHEMBL8101387 0.76 VPS4B (0.45) LMNAMEN1KMT2AHTR1FMAPT
SCHEMBL8101002 0.76 KMT2A (0.46) HTTMEN1KMT2AHTR1FMAPT
SCHEMBL8101435 0.75 HTR1F (0.47) LMNAMEN1KMT2AHTR1FMAPT
SCHEMBL8116663 0.75 JAK2 (0.46) LMNAMEN1KMT2AHTR1FMAPT
Acetic Acid SCHEMBL8555874 0.75 ALDH1A1 (0.42) LMNAHTTMEN1KMT2AHTR1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
EP-0749962-B1 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles LILLY CO ELI (US) 2000-11-02 EP disclosed
US-5814653-A SUMATRIPTAN FOR RELIEF OF MIGRAINE PAIN AND OTHER DISORDERS ASSOCIATED WITH PEPTIDE EXTRAVASATION DIE TO STUMULATION OF THE TRIGEMINAL GANGLIA; 5-HT 1F AGONISTS ELI LILLY AND COMPANY (US) 1998-09-29 US disclosed
US-5708187-A MIGRANE HEADACHES ELI LILLY AND COMPANY (US) 1998-01-13 US disclosed
EP-0749962-A1 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles ELI LILLY AND COMPANY (US) 1996-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D LMNA 4061/4885HTT 131/4885MEN1 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.